• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

thomas.rasmussen@unimelb.edu.au

Credentials


Position
Clinical (Associate Professor)
Department of Infectious Diseases
Education
PhD
Aarhus University
Masters
Aarhus University
ORCID

0000-0001-5354-2442

A/Prof Thomas Rasmussen

Clinical (Associate Professor)
Department of Infectious Diseases

94 Scholarly works
8 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials
    DOI: 10.1016/S2352-3018(25)00373-X
  • 2026

    Journal article

    Immunological dysfunction associated with SARS-CoV-2 persistence in immunocompromised patients
    DOI: 10.1093/cei/uxag022
  • 2025

    Journal article

    Pomalidomide enhances CD8 T and NK cell mediated killing of HIV-infected cells
    DOI: 10.1016/j.ebiom.2025.106004
  • 2025

    Journal article

    Factors Influencing Virologic Control During Analytical Treatment Interruptions in HIV Cure Trials - a Pooled Analysis of Individual-Level Data
    DOI: 10.1093/infdis/jiaf163
  • 2022

    Research grants (other domestic)

    Eliminating HIV That Persists on ART by Antogonising the Apoptosis Regulator, BCL-2
  • 2021

    Research grants (international)

    Delaney AIDS Research Enterprise to Find a Cure (DARE 3.0) - (2021-2026) - SUBAWARD 7
  • 2019

    Research Contracts

    Effects of Novel Peptides on Hiv Latency and Hiv-Specific T-Cell Function
Thomas Rasmussen

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025
    DOI: 10.20411/pai.v10i2.885
  • 2025

    Journal article

    Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir
    DOI: 10.1128/jvi.01676-24
  • 2024

    Journal article

    7.1 – 00113 Safety and PD-1 receptor occupancy with low dose Nivolumab in adults living with HIV on antiretroviral therapy: NIVO-LD
    DOI: 10.1016/j.jve.2024.100430
  • 2024

    Journal article

    Protocol for measuring killing capacity and intracellular cytokine production of human HIV antigen-specific CD8 T cells using flow cytometry
    DOI: 10.1016/j.xpro.2024.103231
  • 2024

    Journal article

    Cutaneous leishmaniasis in a patient with psoriatic arthritis treated with tumour necrosis factor-α inhibitor
    DOI: 10.1080/03009742.2023.2295627
  • 2023

    Journal article

    GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy
    DOI: 10.1016/j.isci.2023.108165

RECENT PROJECTS

  • 2021

    Research grants (international)

    Delaney AIDS Research Enterprise to Find a Cure (DARE 3.0) - M&O - (2021-2026) - SUBAWARD 10
  • 2021

    Research Contracts

    Safety, Immunogenicity and Efficacy of Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (ART): NIVO-LD

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224